Press Release October 19, 2022

Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly

The Life Sciences Licensing Team advised Nimbus Therapeutics on its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide development and commercialization of novel targeted therapies that activate a specific isoform of AMPK for the treatment of metabolic diseases.  Nimbus is eligible under the agreement to receive up to $496 million, inclusive of research funding and potential milestone payments, in addition to royalties on net sales ranging from mid-single to low double-digits.

Nimbus Therapeutics is a clinical-stage company working to design and develop breakthrough medicines through its powerful and comprehensive computational drug discovery engine.

The Goodwin team was led by Sarah Solomon and Alexandra Haas, with invaluable support from Bill Collins, Chris Denn, Kathleen Kean and Dan Karelitz.

For more details, read the press release and article in BioSpace, Endpoints News, and Fierce Biotech.